Article Text

AB0452 Changes in Lipoproteins Associated with Tocilizumab Treatment Do not Influence the Atherogenic Index of Plasma of Rheumatoid Arthritis Patients
  1. F. Cacciapaglia1,
  2. A. Maria Grazia2,
  3. A. Rinaldi2,
  4. C. Scioscia2,
  5. G. Lopalco2,
  6. M. Covelli2,
  7. F. Iannone2,
  8. G. Lapadula2
  1. 1Internal Medicine Unit - Rheumatology Outpatients Clinic, ASL Brindisi - “N. Melli” Hospital, San Pietro
  2. 2Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, Medical School, University of Bari, Bari, Italy


Background Interleukin-6 inhibition by tocilizumab (TCZ) has been associated with changes in the lipoprotein profile [1], which could adversely impact cardiovascular (CV) risk in patients with rheumatoid arthritis (RA) [2].

Objectives The aim of this observational study is to evaluate the effect of TCZ on lipoproteins and on the atherogenic index of plasma (AIP), a useful predictor of cardiovascular risk [3].

Methods Forty patients (36 female; age 55±11 yrs) with active RA and an inadequate response to DMARDs treated with 8 mg/kg TCZ every 4 weeks intravenously, were consecutively enrolled with a 1 year follow-up. Patients on hypolipidemic therapy were excluded. Before and on week 12, 24 and 52, DAS28 and CDAI were evaluated, and blood samples were taken to assess plasmatic levels of total cholesterol (TC), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides (TG), and to calculate the AIP (LogTG/HDL).

Results During the first 24 weeks of TCZ treatment we observed a progressive increase of about 10% for TC and TG, and of about 30% for LDL-C and HDL-C compared to baseline. In the subsequent 6 months there was a reduction of TC and TG, whereas HDL-C and LDL-C continued to increase to about 40% compared to baseline (see Table). Lipid changes were inversely correlated with both the disease activity scores DAS28 and CDAI. Contextually the AIP was stable around 1, with no statistically significant changes. During the observational period no CV events have been observed.

Table 1

Conclusions TCZ acts on the lipid profile increasing all the lipoprotein fraction, especially during the first 6 months of treatment, probably by a direct hepatic effect [4]. On the contrary the net effect of TCZ on AIP, and consequently on CV risk, would seem to be irrelevant.


  1. Kawashiri SY et al. Rheumatol Int. 2011

  2. Souto A et al. Arthr Rheumatol 2015

  3. Gasevic D et al. Lipids Health Dis. 2014

  4. Strang AC et al. Atherosclerosis 2013

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.